Oligonucleotides Analytical Development and CMC on August 25-27, 2025 in Boston, United States

Uniting Biotech and Pharma Experts to Exchange Insights on Oligonucleotide Analytical Development and CMC.

Despite milestone progress, such as Avidity securing breakthrough designation for their oligo conjugate, significant challenges persist across the oligo landscape in impurity profiling, drug characterisation, efficient scale-up, and regulatory alignment.

Join 80+ industry experts from analytical development, process development, CMC, analytical chemistry, and quality control at the 4th Oligonucleotide Analytical Development and CMC Summit to collaborate, network and learn cutting-edge strategies that are tackling the unique challenges in oligo analytical development and CMC scale-up.

Gain actionable insight from case studies, presentations and deep dive discussions from Sarepta, Ionis, Biogen, Novo Nordisk, GSK, Wave Life Science, Denali, PepGen, Avidity, Alnylam and more, to advance and reshape the future of oligonucleotide drug development.

URLs:

Tickets: https://go.evvnt.com/3149372-2?pid=10008

Brochure: https://go.evvnt.com/3149372-3?pid=10008

Time: 8:00 AM - 4:30 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 3598.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3098.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Service and Expertise Providers - 3 Day Pass (Conference + Workshop Day): USD 4398.00,

Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Bao Cai, Executive Director of Process Development, Sarepta Therapeutics, Benjamin Rogers, Associate Director/Principal Scientist, Oligonucleotide and Small Molecule CMC, Denali Therapeutics Inc., Debasis Patra, Senior Director, Vice President and Head of Chemistry, Manufacturing, and Controls, OliX Pharmaceuticals, Eric Shi, Associate Director, GlaxoSmithKline, Evan Santos, Senior Research Associate, Manufacturing and Operations, Ionis Pharmaceuticals, Inc., George Bou-Assaf, Associate Director Analytical and CMC Development, Biogen, Hagen Cramer, Chief Technology Officer, QurAlis Corp., Hongling Han, Senior Director, PepGen, Kok-Seong Lim, Cell and Gene Therapy CMC Expert, Independent Expert, Lianxiu Guan, Senior Principal Scientist, Amgen Inc., Matt McQueen, scientist, Avidity Biosciences, Inc., Paul Koevoets, Director Analytical Chemistry, Vico Therapeutics BV, Philip Ross, Senior Director - Analytical Development , Quality Control and Chemistry, Manufacturing and Controls, Wave Life Sciences Ltd., Satya Kuchimanchi, Senior VP, Technical Operations, CMC, CAMP4 Therapeutics, Stephen Dietrich, Director - RNA AND DS MS AND T, Sarepta Therapeutics, Tyler Johnson, Analytical Scientist II, NN-DRNA Early Development, Novo Nordisk, Yansheng Wu, Vice President and Global Head of Regulatory, Chemistry, Manufacturing and Controls, Hongene Biotech Corporation